摘要
目的比较使用奈达铂(NDP)与顺铂(DDP)胸腔灌注治疗非小细胞肺癌(Nonsmall-cell lung cancer,NSCLC)恶性胸腔积液的临床疗效、患者生活质量及不良反应。方法 79例NSCLC患者随机分为2组,其中治疗组39例,对照组40例。治疗组给予奈达铂40 mg/m2+地塞米松10 mg溶于40 mL生理盐水中,胸腔注入给药;对照组给予顺铂40 mg/m^2+地塞米松10 mg溶于40 mL生理盐水中,胸腔注入给药。两组患者均给予相同的常规对症治疗,观察两组临床疗效、生活质量改善情况及不良反应。结果治疗组有效率为89.7%,对照组有效率为62.5%,两组比较差异有统计学意义(P<0.05)。治疗组消化道不良反应发生率为20.5%,对照组消化道不良反应发生率为60.0%,两组比较差异有统计学意义(P<0.05)。治疗组的Karnofsky评分为(84.21±11.92)分,高于对照组的(71.86±10.88)分,两组比较差异有统计学意义(P<0.05)。治疗组的生存期为(16.83±3.68)个月,对照组的生存期为(13.11±2.07)个月,两组比较差异有统计学意义(P<0.05)。结论与顺铂相比,奈达铂胸腔灌注治疗NSCLC引起的恶性胸腔积液是一种更有效且不良反应较轻的方法。
Objective To compare the clinical effect,improvement of patient＇ s quality of life and adverse reaction of nedaplain and cisplatin in the treatment of malignant pleural effusion caused by nonsmall-cell lung cancer（NSCLC）.Methods Seventy nine NSCLC patients were divided into treatment group（n =39） and control group（n =40）.Patients in treatment group were given cisplatin（40 mg/m^2） ＋dexamethasone（10 mg） dissolved in 40 mL saline.Patients in control group were given nedaplain（40 mg/m^2） ＋dexamethasone（10 mg） dissolved in 40 mL saline.The drugs were delivered by chest injection.Patients of the two groups were given the same conventional symptomatic treatment.The clinical effect,patient＇ s quality of life and adverse reaction were observed.Results The effective rate of treatment group was higher than that of control group,there was significant difference between the two groups（89.7%vs.62.5%,P〈0.05）.The incidence of gastrointestinal adverse reactions was lower than that of control group,there was significant difference between the two groups（20.5%vs.60.0%,P〈0.05）.The Karnofsky scores of treatment group and control group were 84.21 ±11.92 and 71.86 ± 10.88,there was significant difference between the two groups（P〈0.05）.The survival time of treatment group and control group were 16.83 ±3.68 and 13.11±2.07,there was significant difference between the two groups（P〈0.05）.Conclusion Nedaplain pleural perfusion treatment for malignant pleural effusion induced by NSCLC is a more effective method than cisplatin with lighter degree of adverse reaction.
出处
《实用药物与临床》
CAS
2016年第1期48-51,共4页
Practical Pharmacy and Clinical Remedies
基金
国家自然科学基金项目(81201803)
关键词
奈达铂
顺铂
非小细胞肺癌
胸腔积液
Nedaplain
Cisplatin
Nonsmall-cell lung cancer
Pleural effusion
